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Abstract. Hepcidin, the master regulator of bioavailable iron, is a key mediator of anemia and also plays a central
role in host defense against infection. We hypothesized that measuring hepcidin levels in cord blood could provide an
early indication of interindividual differences in iron regulation with quantifiable implications for anemia, malaria, and
mortality-related risk. Hepcidin concentrations were measured in cord plasma from a birth cohort (N = 710), which
was followed for up to 4 years in a region of perennial malaria transmission in Muheza, Tanzania (2002–2006). At the
time of delivery, cord hepcidin levels were correlated with inflammatory mediators, iron markers, and maternal health
conditions. Hepcidin levels were 30% (95% confidence interval [CI]: 12%, 44%) lower in children born to anemic
mothers and 48% (95% CI: 11%, 97%) higher in placental malaria–exposed children. Relative to children in the lowest
third, children in the highest third of cord hepcidin had on average 2.5 g/L (95% CI: 0.1, 4.8) lower hemoglobin
levels over the duration of follow-up, increased risk of anemia and severe anemia (adjusted hazard ratio [HR] [95%
CI]: 1.18 [1.03, 1.36] and 1.34 [1.08, 1.66], respectively), and decreased risk of malaria and all-cause mortality (adjusted
HR [95% CI]: 0.78 [0.67, 0.91] and 0.34 [0.14, 0.84], respectively). Although longitudinal measurements of hepcidin
and iron stores are required to strengthen causal inference, these results suggest that hepcidin may have utility as a
biomarker indicating children’s susceptibility to anemia and infection in early life.
INTRODUCTION
As the master regulator of bioavailable iron, hepcidin is a
critical mediator of child health in malaria-endemic regions.
The maintenance of adequate iron stores is essential for the
production of hemoglobin and the rapid expansion of red
cell mass that occurs in young children, and iron deficiency
during the first “1,000 days” of development has been linked
to cognitive, motor, and behavioral deficits that can last into
adulthood.1,2 The first 30 months of age also represent a key
window of vulnerability to severe malaria infection and
death.3,4 Until children have developed naturally acquired
resistance against Plasmodium parasites, hepcidin plays a par-
ticularly valuable role in host defense. Within hours of patho-
genic insult, hepcidin expression is induced by cytokines and
causes the increased internalization and degradation of the iron
transporter ferroportin.5–8 The loss of functional ferroportin
causes the inhibition of dietary iron absorption via enterocytes
and promotes sequestration of iron in reticuloendothelial cells
with a net effect of iron restriction from pathogens.6,9,10
Iron restriction is important to the host’s defensive response
across multiple stages of malaria infection. Numerous in vitro
and in vivo studies confirm that reducing iron availability
through application of iron-chelating agents is an effective
method to stunt the proliferation of parasites.11 During the
blood stage, iron deficiency may confer a protective effect by
impairing the ability of Plasmodium falciparum to invade
and propagate between erythrocytes.12 In addition, recent
experiments have also found that hepcidin-induced iron redis-
tribution away from hepatocytes arrests the growth of intra-
hepatocytic parasites and thereby prevents the occurrence
of malaria superinfections.13 Epidemiological studies lend sup-
port to these findings: pregnant women and children who are
iron deficient are observed to have lower risks of malarial
disease,14–18 and pediatric iron supplementation has been
shown to heighten the risk of both clinical and severe
malaria.19,20 In addition to malaria, elevated iron has been
associated with poor prognoses in cases of bacterial and viral
infections21 and may be associated with child mortality in
communities with high burdens of communicable disease.
We hypothesized that measuring hepcidin levels in cord
blood could provide an early indication of interindividual dif-
ferences in iron regulation with quantifiable implications for
child health during the first years of life. To investigate the
theoretical relation between hepcidin and clinical endpoints
known to be sensitive to iron homeostasis, we measured cord
hepcidin levels in a birth cohort of children followed between
2002 and 2006 in a region of perennial malaria transmission
in Muheza, Tanzania. Since little is known about the cross-
sectional correlates of cord hepcidin in malaria-endemic
regions, we first characterized in detail the associations of
hepcidin with host characteristics, maternal health status, and
markers of iron and inflammation in cord, maternal periph-
eral, and placental blood samples collected at the time of
delivery. We then measured the associations between cord
hepcidin and the time to anemia-, malaria-, and mortality-
related outcomes.
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MATERIALS AND METHODS
Ethics. The U.S. National Institutes of Health Inter-
national Clinical Studies Review Committee of the Division
of Microbiology and Infectious Diseases approved the study
procedures, and the institutional review boards of the Seattle
Biomedical Research Institute and the National Institute for
Medical Research in Tanzania provided ethical clearance.
Participating mothers provided written informed consent for
themselves and their newborn child. Mothers enrolled during
labor were reconsented at the first follow-up visit. Prompt care
was provided to sick children in accordance with Tanzanian
Ministry of Health protocols. Blood smear results and hemo-
globin concentrations were evaluated during the study visits,
and health workers had full access to the results for clinical
decision-making. All subsequent laboratory measurements
were performed on deidentified samples.
Study population. The Mother-Offspring Malaria Study,
initiated in 2002 as a prospective birth cohort study of
malaria, has been described in detail previously.22 A total
of 1,045 pregnant women (1,075 offspring) between the ages
of 18 and 45 years who presented for delivery at the Muheza
Designated District Hospital in the Tanga region of Tanzania
between September 9, 2002, and October 13, 2005, were
invited to participate in the investigation; children were
followed up until May 18, 2006. To be eligible for this study,
children had to be 1) born to human immunodeficiency virus
(HIV)–negative mothers, 2) sickle cell disease free, 3) a
singleton birth, and 4) followed for a minimum of 28 days
(Figure 1). At the time of hepcidin measurement, plasma
samples were no longer available for 20% of the originally
recruited sample. However, no substantial differences in
baseline variables were found between children with and
without measured hepcidin; this suggests that, although the
missing hepcidin measurements decreased statistical power,
their absence was unlikely to bias results (Supplemental
Table 1).
Sampling procedures. Trained project nurses and assistant
medical officers administered questionnaires to mothers and
collected clinical information using standardized forms. Mater-
nal peripheral blood samples and placentas were collected at
delivery, and placental blood was extracted from placental
tissue by mechanically pressing full-thickness placental tissue.
Cord blood samples were collected immediately after parturi-
tion from venous umbilical blood vessels using routine pro-
cedures for cord clamping and vessel cannulation. Blood
samples were collected in ethylenediaminetetraacetic acid for
anticoagulation and fractionated by centrifugation at 3,000 g
for 3 minutes. Plasma samples were frozen at −70°C until the
immunoassays were performed. Clinicians monitored chil-
dren’s health statuses during sick visits and at routine visits
occurring on a biweekly basis during the first 12 months of life
and a monthly basis for any follow-up beyond the first year.
Children’s hemoglobin was measured at sick visits and during
routine visits at approximately 3, 6, 12, 18, 24, 30, 36, 42, and
48 months of age. Parasitemia by P. falciparum was deter-
mined after counting 200 leukocytes on Giemsa-stained thick
blood smear of a sample collected by heel or finger prick dur-
ing child visits.
Case definitions. In both the children under 4 years of age
and pregnant women, all-cause anemia and severe anemia
were defined as hemoglobin concentrations < 110 and < 70 g/L,
respectively.23 Malaria was defined as the detection of
P. falciparum parasitemia in peripheral blood. Severe malaria
was identified clinically as a P. falciparum-positive blood
smear with one or more of the following symptoms: severe
anemia (i.e., hemoglobin concentration < 50 g/L), respiratory
distress (i.e., respiratory rate > 50 breaths/minute in neonates
and > 40 breaths/minute in older children with two of the fol-
lowing: nasal flaring, intercostal indrawing, subcostal reces-
sion, and grunting), > 1 convulsion episode in 24 hours, coma
(i.e., Blantyre score < 3), prostration (i.e., inability to sit
upright in a child normally able to do so or drink in a child too
young to sit), hypoglycemia (i.e., blood glucose < 40 mg/dL),
renal failure (i.e., urine output < 12 mL/kg/day), hemoglobin-
uria, jaundice, and shock (i.e., cold extremities, rapid heart
rate, and/or systolic blood pressure < 50 mmHg). Placental
malaria was defined as the detection of P. falciparum para-
sitemia in placental blood.
Laboratory procedures. The 25-amino acid bioactive iso-
form of hepcidin was detected in cord blood plasma using
the hepcidin-25 (human) EIA kit (Bachem, Bubendorf,
Switzerland) as previously described.24 A dilution series of
standard hepcidin-25 was run on each plate with values ranging
FIGURE 1. Selection of the study sample.
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from 25 to 0.05 ng/mL. Sample values were interpolated using
logistic 4-parameter nonlinear curve fitting in GraphPad Prism
software (GraphPad Software, Inc., La Jolla, CA). If hepcidin
readings initially fell outside the linear portion of the standard
curve, samples were rerun at appropriate dilution. If samples
exhibited a high coefficient of variation (> 15%) between
duplicates, they were rerun, and the new value was substi-
tuted. Soluble inflammatory and iron markers in cord, mater-
nal peripheral, and placental blood plasma were measured
using commercially available multiplex, bead-based platforms
(BioPlex®; BioRad, Irvine, CA) and custom-made assay kits
as previously described.25 Samples that did not produce detect-
able concentrations of a given marker were assigned a value of
half the limit of detection of that marker. Sickle cell trait was
determined by cellulose acetate paper electrophoresis (Helena
Laboratories, Beaumont, TX), and α-thalassemia was deter-
mined by polymerase chain reaction.26
Statistical analysis. The statistical approach used to describe
the cross-sectional correlates of hepcidin was adapted from the
methodology used by the Fibrinogen Studies Collaboration.27
Positively skewed continuous variables were loge-transformed
before analysis. Cross-sectional correlations between hepcidin
and continuous traits were first quantified by Pearson’s r.
Mean levels of loge-transformed cord hepcidin were plotted
against the mean for each eighth (i.e., corresponding to
approximately one half of a standard deviation) of continuous
traits. This approach allowed assessment of the shape of any
association with cord hepcidin without assuming linearity a
priori. Univariate linear regressions were then used to evaluate
mean percent differences in hepcidin per level of categorical
variables and by standard deviation of continuous variables;
the mean percent differences were estimated with the formula
(eβ − 1) × 100%, where the β coefficient represents the mean
difference in loge-transformed hepcidin level. The coefficient
of determination (r2) from a linear regression was used to
quantify the proportion of variance in cord hepcidin explained
by the measured correlates.
For the prospective analyses, the primary exposure was
hepcidin measured from cord plasma, which was evaluated
both continuously and in tertiles (histogram provided in Sup-
plemental Figure 1; cutoffs provided in Supplemental Table 2).
Associations of cord hepcidin with repeated measurements of
hemoglobin (N = 6,121 visits) and parasitemia (N = 5,493
visits with ≥ 1 parasite per 200 white blood cells) were evalu-
ated using linear mixed-effects models with village- and child-
specific random effects, quadratic time trends, and adjustment
for placental malaria status, cord blood levels of loge ferritin
and loge C-reactive protein, and concurrent malaria infection
status. Fractional polynomial models of best fit were used to
visualize the nonlinear associations between hemoglobin con-
centrations and age for children with above and below median
cord hepcidin levels. For survival analyses, Cox proportional
hazard models were used to calculate the hazard ratios (HRs)
for the times to the first episode of anemia, severe anemia,
malaria, severe malaria, and child death. Models were
adjusted for potential confounders, including village of resi-
dence, placental malaria status, and cord blood levels of loge
ferritin and loge C-reactive protein. To allow HRs to be com-
pared informatively across any pair of hepcidin tertiles and
without depending on the precision within any arbitrarily
selected baseline group, 95% confidence intervals (CIs) were
estimated from floated variances.28 All statistical analyses
were performed using Stata, version 12 (StataCorp LP, Col-
lege Station, TX). P values were from two-sided tests.
RESULTS
In 710 children followed up over 1,482.0 person-years
(median = 2.2 years per child), 639 experienced anemia, 274
experienced severe anemia, 590 experienced malaria, 98 expe-
rienced severe malaria, and 32 died (Supplemental Table 2).
Child deaths were primarily caused by infectious diseases,
including malaria (N = 11), sepsis, fevers of unknown origin,
and diarrheal diseases (N = 9), respiratory infections (N = 4),
and meningitis (N = 3). Deaths from noncommunicable
diseases included congenital anomalies (N = 2), leukemia
(N = 1), intestinal obstruction (N = 1), and aspiration (N = 1).
The overall median concentration of cord hepcidin was
28.1 ng/mL (interquartile range: 14.3, 50.1).
Cross-sectional correlates of cord hepcidin. Table 1
describes the prevalence of the categorical traits in the study
sample and their cross-sectional associations with cord
hepcidin. Although cord hepcidin levels did not vary statisti-
cally significantly by sex, hemoglobin S trait, α-thalassemia,
maternal gravidity, bed net status at enrollment, or detection
of interleukin 4 in blood samples, cord hepcidin levels did
appear to reflect maternal anemia and malaria exposure near
the time of delivery. In the 594 dyads with known maternal
hemoglobin status, hepcidin was 30% (95% CI: 12%, 44%)
lower in infants born to mothers with anemia, defined as
hemoglobin < 110 g/L, at the time of delivery. Infants born
during the high season for malaria transmission had 28%
(95% CI: 5%, 57%) higher hepcidin than children born dur-
ing the low-transmission season. Similarly, placental malaria–
exposed infants had 48% (95% CI: 11%, 97) higher cord
hepcidin relative to unexposed infants. In addition, hepcidin
levels were elevated in children with detectable concentrations
of interferon-γ from all three of the blood sources.
Figures 2 and 3, as well as Supplemental Figures 2 and 3,
explore the shapes of the associations between the continu-
ous traits and loge hepcidin. The shape plots in Figure 2 sug-
gest that cord hepcidin correlates neither with birth weight
(Figure 2A) nor with maternal age (Figure 2B). Consistent
with the aforementioned relationship between cord hepcidin
and maternal anemia, cord hepcidin was positively, but weakly
associated with maternal hemoglobin levels as a continuous
trait (r = 0.08) (Figure 2C). Post hoc analyses showed that
mothers’ hemoglobin levels strongly correlated with their
peripheral blood ferritin levels: maternal hemoglobin increased
by 4.8 g/L (95% CI: 1.6, 7.9) for each standard deviation
increase in maternal peripheral blood ferritin, suggesting iron
deficiency was likely a key contributor to the observed cases
of maternal anemia.
Of the cord blood markers presented in Figure 3, hepcidin
was generally positively associated with the measured inflam-
matory mediators, excluding interleukin 5 (Figure 3E). The
strongest correlations were with C-reactive protein (r =
0.31), ferritin (r = 0.28), and tumor necrosis factor (r = 0.26)
(Figure 3A, H, and I). Although the shape of association
between tumor necrosis factor receptor I and hepcidin
reflected that of tumor necrosis factor (Figure 3B), tumor
necrosis factor receptor II did not appear to be associated
with cord hepcidin levels (Figure 3C). In addition, although
cord levels of soluble transferrin receptor had an overall null
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correlation with hepcidin (in part, due to an outlying lowest
eighth), these data provide an indication that soluble trans-
ferrin receptor concentrations in cord blood may have an
inverse association with cord hepcidin levels (Figure 3J).
The correlations between hepcidin and markers from the
maternal peripheral blood (Supplemental Figure 2) are con-
sistent in shape with those of the cord samples (Figure 3).
Although most inflammatory mediators were positively and
approximately linearly associated with cord hepcidin levels,
tumor necrosis factor receptor II, interleukin 5, and soluble
transferrin receptor measured in maternal peripheral blood
were, again, not observed to be associated with hepcidin
(Supplemental Figure 2C, E, and J). In the placental blood
sample, hepcidin levels were associated with the same inflam-
matory mediators, but also had additional modest, positive
correlations with interleukin 5 (r = 0.10) and soluble transfer-
rin receptor (r = 0.21) (Supplemental Figure 3E and J).
Table 2 summarizes the continuous traits and their cross-
sectional associations with cord hepcidin. Overall, hepcidin
levels were positively correlated with markers of inflamma-
tion, including interleukins 6 and 10. With the exceptions of
interleukin 5 and soluble transferrin receptor, relations
between blood markers and cord hepcidin were materially
consistent between cord, maternal peripheral, and placental
samples. Across all continuous traits, C-reactive protein
levels measured in placental blood were the one most highly
correlated with cord hepcidin levels (r: 0.37, 95% CI: 0.30,
0.43). Of note, placental C-reactive protein levels were, on
average, 390% (95% CI: 230%, 630%) higher in placental
malaria-positive dyads than those of placental malaria-negative
pairs. Moreover, adjustment for placental levels of C-reactive
protein caused the correlations of cord hepcidin with high-
transmission season at delivery and placental malaria to lose
statistical significance (P = 0.22 and 0.76, respectively); in
TABLE 1
Cross-sectional associations of cord hepcidin with categorical traits measured at the time of delivery
Variable Total N (%)
Mean percent difference (95% CI)
compared with reference group P value
Clinical markers Sex 710 0.54
Female 340 (47.9) Reference
Male 370 (52.1) −6 (−23, 15)
Sickle cell trait 708 0.50
AA 592 (83.6) Reference
AS 116 (16.4) 10 (−16, 44)
α-thalassemia 699 0.53
α/α 321 (45.9) Reference
α/α-3.7 293 (41.9) −7 (−25, 15)
α-3.7/α-3.7 85 (12.2) −16 (−39, 16)
Gravidity 710 0.47
Primigravidae 202 (28.5) Reference
Secundigravidae 167 (23.5) −5 (−28, 26)
Multigravidae 341 (48.0) −13 (−31, 10)
Maternal anemia at delivery 594 0.002**
Anemia− 259 (43.6) Reference
Anemia+ 335 (56.4) −30 (−44, −12)
Delivery season 710 0.01*
Low malaria transmission 369 (52.0) Reference
High malaria transmission 341 (48.0) 28 (5, 57)
Placental malaria 710 0.008*
Placental malaria− 613 (86.3) Reference
Placental malaria+ 97 (13.7) 48 (11, 97)
Bed net at enrollment 594 0.12
Bed net+, treated 90 (15.2) Reference
Bed net+, untreated 274 (46.1) 9 (−22, 51)
Bed net− 230 (38.7) −16 (−40, 18)
Blood markers Interleukin 4CB 710 0.57
Below limit of detection 640 (90.1) Reference
Detectable 70 (9.9) 10 (−21, 54)
Interleukin 4PER 667 0.08
Below limit of detection 597 (89.5) Reference
Detectable 70 (10.5) 35 (−3, 88)
Interleukin 4PLC 680 0.37
Below limit of detection 520 (76.5) Reference
Detectable 160 (23.5) 12 (−12, 42)
Interferon γCB 710 0.04*
Below limit of detection 559 (78.7) Reference
Detectable 151 (21.3) 30 (2, 66)
Interferon γPER 667 0.06
Below limit of detection 527 (79.0) Reference
Detectable 140 (21.0) 27 (−1, 63)
Interferon γPLC 680 0.002**
Below limit of detection 320 (47.1) Reference
Detectable 360 (52.9) 39 (13, 71)
CB = cord blood; CI = confidence interval; PER = maternal peripheral blood; PLC = placental blood.
*P < 0.05,
**P < 0.005.
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FIGURE 2. Mean loge hepcidin levels within eighths of clinical markers measured at the time of delivery plotted against the mean of the
clinical marker value in each eighth for assessment of the shape of association with hepcidin. Bars: 95% confidence interval (CI). *P < 0.05,
**P < 0.005, ***P < 0.0005.
FIGURE 3. Mean loge hepcidin levels within eighths of loge cord blood markers plotted against the mean of the cord blood marker value
in each eighth for assessment of the shape of association with cord hepcidin: (A) tumor necrosis factor, (B) tumor necrosis factor receptor I, (C)
tumor necrosis factor receptor II, (D) interleukin 1β, (E) interleukin 5, (F) interleukin 6, (G) interleukin 10, (H) C-reactive protein, (I) ferritin,
and (J) soluble transferrin receptor. Bars: 95% confidence interval (CI). *P < 0.05, **P < 0.005, ***P < 0.0005. CRP = C-reactive protein; IL =
interleukin; sTfR = soluble transferrin receptor; TNF = tumor necrosis factor; TNF-RI = tumor necrosis factor receptor I; TNF-RII = tumor
necrosis factor receptor II.
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contrast, the inverse association between cord hepcidin and
maternal anemia at delivery remained significant after control-
ling for C-reactive protein (P = 0.007).
In summary, cord hepcidin levels reflect the maternal
health conditions of anemia and placental malaria at the time
of delivery and are sensitive to inflammatory and iron-
related processes at the maternal–child interface. In total,
the measured markers explained approximately 37% of the
variance in cord hepcidin level. Although the high levels of
correlation between blood markers make it difficult to disen-
tangle the individual relations with hepcidin, C-reactive pro-
tein, tumor necrosis factor, and ferritin appear to be the
strongest correlates in these analyses.
Cord hepcidin and risks of pediatric anemia, malaria, and
mortality. In adjusted linear mixed-effects models, children
in the top third of the cord hepcidin distribution had, on
average over the duration of follow-up, 2.5 g/L (95% CI: 0.1,
4.8) lower levels of hemoglobin (P = 0.038) than children in
the lowest third. The best-fit fractional polynomials for the
time profile of hemoglobin in children with above and below
median levels of cord hepcidin provide evidence that the
divergence in hemoglobin trajectories precedes the nadir of
the physiologic anemia of infancy and can persist through
the first 3 years of life (Figure 4). Confirming the clinical
relevance of these observations, children in the highest ter-
tile for cord hepcidin had increased risk of all-cause anemia
(adjusted HR [95% C]): 1.18 [1.03, 1.36]) (Figure 5) and
severe anemia (adjusted HR [95% CI]: 1.34 [1.08, 1.66])
(Supplemental Figure 4) relative to the lowest tertile. In
addition, children with relatively higher concentrations of
cord hepcidin also had decreased risk of first malaria infec-
tion (i.e., based on survival analyses of time to first para-
sitemia) (adjusted HR [95% CI] for top versus bottom third:
0.78 [0.67, 0.91]) and all-cause mortality (adjusted HR [95%
CI] for top versus bottom third: 0.34 [0.14, 0.84]) (Figure 5).
Notably, only one of the 11 malaria-related deaths occurred
in a child in the highest tertile of cord hepcidin (Figure 6).
Despite these relations, cord hepcidin levels did not appear
to be significantly associated with a child’s risk of severe
malaria (adjusted HR [95% CI] for top third versus bottom
third: 1.27 [0.89, 1.80]) (Supplemental Figure 4) nor repeated
measurements of parasitemia (mean percent difference [95%
CI] in parasite density over the duration of follow-up for top
versus bottom third cord hepcidin: 10% [−15, 41]).
DISCUSSION
Using data from a birth cohort of 710 children residing in
a perennially endemic, high-transmission region of Tanzania,
we observed that cord hepcidin levels are sensitive to inflam-
matory mediators, iron markers, and maternal health condi-
tions at the time of delivery. Although roughly one-third of
the variance in cord hepcidin was attributable to the acute
conditions measured at the time of birth, the longitudinal
TABLE 2
Cross-sectional associations of cord hepcidin with continuous traits measured at the time of delivery
Variable Total Mean (SD)
Mean percent difference (95% CI)
per one SD higher level P value
Clinical markers Birth weight, kg 710 3.2 (0.4) −2 (−12, 8) 0.67
Maternal age, years 710 25.9 (6.1) −5 (−14, 5) 0.35
Maternal hemoglobin, g/L 594 108.3 (40) 13 (1, 26) 0.04*
Blood markers Loge tumor necrosis factorCB 710 4.6 (1.2) 43 (30, 57) < 0.001**
Loge tumor necrosis factorPER 667 3.0 (2.0) 32 (19, 45) < 0.001**
Loge tumor necrosis factorPLC 680 5.8 (0.8) 33 (21, 47) < 0.001**
Loge tumor necrosis factor-receptor ICB 710 7.6 (0.7) 18 (7, 31) 0.001**
Loge tumor necrosis factor-receptor IPER 667 6.9 (0.7) 28 (16, 42) < 0.001**
Loge tumor necrosis factor-receptor IPLC 680 8.5 (0.9) 26 (14, 39) < 0.001**
Loge tumor necrosis factor-receptor IICB 710 5.8 (2.0) −2 (−12, 8) 0.63
Loge tumor necrosis factor-receptor IIPER 667 3.7 (3.6) −8 (−17, 2) 0.13
Loge tumor necrosis factor-receptor IIPLC 680 6.7 (1.1) −1 (−11, 10) 0.85
Loge interleukin 1βCB 710 1.6 (1.9) 27 (15, 39) < 0.001**
Loge interleukin 1βPER 667 0.4 (2.4) 29 (16, 43) < 0.001**
Loge interleukin 1βPLC 680 4.2 (1.1) 20 (9, 34) < 0.001**
Loge interleukin 5CB 710 0.3 (2.2) 2 (−8, 13) 0.68
Loge interleukin 5PER 667 0.1 (2.4) 0 (−10, 11) 0.98
Loge interleukin 5PLC 680 1.8 (1.5) 15 (4, 27) 0.008*
Loge interleukin 6CB 710 2.0 (1.9) 14 (3, 26) 0.009*
Loge interleukin 6PER 667 2.7 (1.6) 23 (11, 36) < 0.001**
Loge interleukin 6PLC 680 6.4 (1.3) 26 (14, 39) < 0.001**
Loge interleukin 10CB 710 0.7 (2.0) 30 (17, 43) < 0.001**
Loge interleukin 10PER 667 2.0 (1.6) 15 (4, 28) 0.006*
Loge interleukin 10PLC 680 2.6 (1.4) 27 (15, 40) < 0.001**
Loge C-reactive proteinCB 707 −0.3 (1.4) 54 (39, 69) < 0.001**
Loge C-reactive proteinPER 651 3.1 (1.9) 38 (25, 53) < 0.001**
Loge C-reactive proteinPLC 676 1.6 (1.9) 64 (49, 80) < 0.001**
Loge ferritinCB 710 4.6 (1.0) 46 (32, 60) < 0.001**
Loge ferritinPER 667 3.0 (1.4) 27 (15, 40) < 0.001**
Loge ferritinPLC 680 6.6 (0.9) 29 (16, 43) < 0.001**
Loge soluble transferrin receptorCB 707 8.2 (0.6) 6 (−4, 18) 0.21
Loge soluble transferrin receptorPER 651 8.4 (0.7) −3 (−12, 8) 0.59
Loge soluble transferrin receptorPLC 676 9.7 (1.2) 34 (21, 48) < 0.001**
CB = cord blood; CI = confidence interval; PER = maternal peripheral blood; PLC = placental blood; SD = standard deviation.
*P < 0.05,
**P < 0.005.
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investigation suggests that cord hepcidin may provide an
early indication of persistent interindividual differences in
iron regulation. Children with relatively higher cord hepcidin
levels had heightened susceptibility to anemia and protection
from first malaria infection and mortality during the early
life course. These results are consistent with the hypothesis
that deleterious effects of increased hepcidin on iron avail-
ability for erythropoiesis may be counterbalanced by benefi-
cial effects for pathogen control.29
Similar to the pediatric studies that have found high con-
centrations of hepcidin during episodes of malaria para-
sitemia,30–35 we observed that cord hepcidin levels were
elevated for children born during the high-transmission season
and to mothers experiencing placental malaria at delivery.
This link between placental malaria infection and hepcidin
also aligns with a genome-wide expression analysis that
found malaria-infected placentas had a 4-fold upregulation of
hepcidin RNA.36 However, our results differ from the findings
of the Van Santen and others’ (2011) study, which found no
association of placental malaria with cord hepcidin levels in a
small sample (N = 69) of primigravid Gabonese mother–child
dyads.37 With the exception of tumor necrosis factor receptor II
and interleukin 5, loge hepcidin levels had continuous, approx-
imately linear positive associations with the inflammatory
mediators, which were highly consistent across the cord,
maternal peripheral, and placental blood samples. Of the
measured blood markers, the inflammatory marker C-reactive
protein was the strongest correlate of hepcidin. The strength
of this association may be attributable, in part, to the fact that
hepcidin is more tightly temporally coupled with C-reactive pro-
tein than cytokines, which have shorter half-lives, in the acute-
phase reaction that is activated by normal birth processes.38
Markers of iron status were also linked to cord hepcidin
levels. In agreement with a recent study of children born to
mothers with severe iron deficiency anemia,39 we found that
children born to mothers with anemia at the time of delivery
had markedly lower cord hepcidin levels, an association that
FIGURE 4. Fractional polynomial best-fit model of children’s
hemoglobin concentrations over follow-up by age in weeks, stratified
by cord hepcidin level at birth (N = 683 children, N = 6,121 hemo-
globin measurements). The median hepcidin level, 28.1 ng/mL, was
derived from the full population with available hepcidin measure-
ments (N = 710). In linear mixed-effects models adjusted for placen-
tal malaria, malaria infection status, and cord blood levels of ferritin
and C-reactive protein with village- and child-specific random
effects and quadratic time trends, children with above median cord
hepcidin levels had on average 2.4 g/L (95% confidence interval
[CI]: 0.5, 4.3) lower hemoglobin levels (P = 0.012) over the duration
of follow-up.
FIGURE 5. Hazard ratios (HRs) for (A) anemia, (B) malaria, and (C) all-cause mortality by tertile of cord hepcidin (N = 707). Gray trian-
gles indicate univariate models; black squares indicate models with further adjustment for village, placental malaria status, and cord levels of
ferritin and C-reactive protein. Tertile cutoffs (i.e., 0.195–19.6 ng/mL for tertile 1, 19.7–41.6 ng/mL for tertile 2, and 41.7–319 ng/mL for tertile
3) were derived from the full population with available hepcidin measurements (N = 710); 95% confidence intervals (CIs) were estimated
from floated variances. P values were from tests of heterogeneity. Assuming a log-linear relationship, the adjusted HRs (95% CI) for a one
standard deviation higher value of cord hepcidin were 1.07 (0.99, 1.17) for anemia, 0.91 (0.83, 0.98) for malaria, and 0.85 (0.61, 1.18) for
all-cause mortality.
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was robust to further adjustment for placental inflammation.
Consistent with prior investigations, cord hepcidin had a pos-
itive, dose–response relationship with cord ferritin.
40,41 The
positive association between cord hepcidin and placental
levels of soluble transferrin receptor was initially unexpected
given earlier findings of an inverse association from the
transgenic Thep27 mouse line, in which fetal hepcidin from
constitutively hepcidin-expressing offspring was shown to
downregulate placental transferrin receptor mRNA.42 How-
ever, further investigation showed that high (i.e., above
median) placental levels of soluble transferrin receptor were
coincident with lowered maternal ferritin (P = 0.019, Wilcoxon
rank-sum test) and normal cord ferritin (P = 0.48, Wilcoxon
rank sum test), suggesting that the elevated placental soluble
transferrin receptor could be, as previously described, a com-
pensatory mechanism by which the placentas of iron-depleted
mothers may enhance transfer of iron to the fetuses despite
maternal iron deficiency, thereby mediating conflicting
maternal–fetal iron demands.43
Building on the hypothetical framework of the Atkinson
and others’ (2015) study that explored whether healthy
child hepcidin concentrations could influence subsequent
susceptibility to malaria, we investigated the prospective
associations of cord hepcidin with risks of anemia, malaria,
and mortality.35 Unlike the earlier study based on older
Kenyan children,35 we did observe that the cord hepcidin
was associated with modestly delayed onset of early malaria
infections, findings which resonate with mouse models of
hepcidin-mediated malaria protection.13,44 Nevertheless,
higher hepcidin levels were not significantly associated with
decreased parasitemia nor severe malaria risk. A possible
explanation is that hepcidin may be protecting children from
early life infections by inhibiting liver-stage growth, as has
been shown in murine models, but not materially altering chil-
dren’s ability to control the severity of infections that reach
the blood stage.13
The findings that hepcidin could be associated with
increased risk of anemia and decreased risk of all-cause mor-
tality could be of greater public health interest. Overall, these
results add to the growing concern that elevated hepcidin can
impair pediatric iron absorption and promote anemia during
critical periods of child development. However, we note that
the relationship between hepcidin and anemia risks were
nonlinear, and further research will be needed to understand
the mechanisms underlying the threshold effects. Although
the cross-sectional analyses suggest measuring hepcidin at the
time of delivery may be inefficient (i.e., due to the hepcidin’s
substantial correlations with inflammatory mediators stimu-
lated by the birth process), there may be value in ascertaining
children’s “usual” levels of hepcidin at later time points (e.g.,
through monthly measurement during the first 3 months). If
the usual hepcidin level in infancy could serve as a prognostic
indicator of a child’s future iron regulation, then hepcidin test-
ing could facilitate the targeted distribution of iron to those
children who are most likely to absorb and use it.45–47 On the
other hand, if the relation between low hepcidin and suscepti-
bility to mortality is a true association and, hypothetically,
mediated by iron availability (i.e., if low cord hepcidin ! ele-
vated iron absorption ! increased mortality), then providing
additional iron to children with lower baseline levels of hepcidin
without accounting for contemporaneous infectious disease
risk could, in theory, make them more vulnerable to early
death, such has been observed in the pediatric multinutrient
supplementation trials.19,20 Future investigations should also
consider whether interindividual differences in hepcidin could
manifest in differential susceptibility to other iron-requiring
pathogens, such as Vibrio spp.48 and HIV-1, or macrophage-
tropic pathogens, such asMycobacterium tuberculosis.21
To date, this is the largest study to measure cord hepcidin
in sub-Saharan Africa and the first to prospectively investigate
the associated risks of anemia, malaria, and mortality from
the time of birth. Nevertheless, this study had some limita-
tions. First, the blood markers examined here are known to
fluctuate rapidly and are highly influenced by the acute condi-
tions (e.g., duration of labor, gestational age) at the time of
birth. Second, consideration of reverse causation is necessary
FIGURE 6. The distribution of child deaths by tertile of cord hepcidin. Tertile cutoffs (i.e., 0.195–19.6 ng/mL for tertile 1, 19.7–41.6 ng/mL for
tertile 2, and 41.7–319 ng/mL for tertile 3) were derived from the full population with available hepcidin measurements (N = 710). FUO = fever
of unknown origin.
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for interpreting the cross-sectional correlates of hepcidin
described here; for example, it is known that hepcidin levels
can both respond to and control circulating iron in the
plasma.49 Third, additional studies with longitudinal measure-
ments of hepcidin and iron stores are required to strengthen
causal inference and to further evaluate whether iron absorp-
tion and/or availability are part of the mechanistic pathways
underlying these prospective associations. Finally, the general-
izability of this study is likely limited to regions with high
infectious disease burdens. We also recognize that the overall
distribution of cord hepcidin levels were low compared with
reference standards measured in European neonates, possibly
reflecting differences in dietary iron and genetics.41
In conclusion, the results of this study highlight the likely
involvement of hepcidin in the maintenance of iron homeo-
stasis at the maternal–fetal interface and suggest that mea-
suring hepcidin during infancy may provide an early
indication of a child’s future susceptibility to anemia and iron-
requiring pathogens.
Received March 17, 2016. Accepted for publication May 6, 2016.
Published online June 27, 2016.
Note: Supplemental figures and tables appear at www.ajtmh.org.
Acknowledgments: We thank the families who have participated in
this study.
Financial support: This work was supported by the Intramural
Research Program of the National Institute of Allergy and Infectious
Diseases, National Institutes of Health (http://www.niaid.nih.gov/),
the Bill & Melinda Gates Foundation (grant number 29202, http://
www.gatesfoundation.org/), the Grand Challenges in Global Health
Initiative (grant number 1364, http://grandchallenges.org/), the
National Institutes of Health Fogarty International Center (grant
number D43 TW005509, http://www.fic.nih.gov/), and the National
Institutes of Health (grant number R01A152059 to Patrick E.
Duffy). During the duration of study, Elizabeth B. Brickley and
Natasha Spottiswoode were supported by the National Institutes of
Health Oxford Cambridge Scholars Program (http://oxcam.gpp.nih
.gov/). Hal Drakesmith is supported by the Medical Research Coun-
cil, United Kingdom (http://www.mrc.ac.uk/).
Disclaimer: The funder had no role in the study design, data gather-
ing, analysis, interpretation, or writing of the report. The corre-
sponding author had full access to all the data in the study and had
final responsibility for the decision to submit for publication
Authors’ addresses: Elizabeth B. Brickley, Laboratory of Malaria
Immunology and Vaccinology, National Institute of Allergy and
Infectious Diseases, Bethesda, MD, Department of Public Health
and Primary Care, University of Cambridge, Cambridge, United
Kingdom, and Department of Epidemiology, Dartmouth College
Geisel School of Medicine, Lebanon, NH, E-mail: elizabeth.b
.brickley@dartmouth.edu. Natasha Spottiswoode, Laboratory of
Malaria Immunology and Vaccinology, National Institute of Allergy
and Infectious Diseases, Bethesda, MD, Weatherall Institute of
Molecular Medicine, University of Oxford, Oxford, United Kingdom,
and Department of Microbiology and Immunology, Columbia Univer-
sity College of Physicians and Surgeons, New York, NY, E-mail:
nns2115@cumc.columbia.edu. Edward Kabyemela, Mother-Offspring
Malaria Studies Project, Muheza Designated District Hospital, Muheza,
Tanzania, E-mail: earkabyemela@yahoo.com. Robert Morrison,
Michal Fried, and Patrick E. Duffy, Laboratory of Malaria Immunol-
ogy and Vaccinology, National Institute of Allergy and Infectious Dis-
eases, Bethesda, MD, E-mails: bob.morrison@cidresearch.org, michal
.fried@nih.gov, and patrick.duffy@nih.gov. Jonathan D. Kurtis, Center
for International Health Research, Rhode Island Hospital, Providence,
RI, E-mail: jonathan_kurtis@brown.edu. Angela M. Wood, Public
Health and Primary Care, University of Cambridge, Cambridge,
United Kingdom, E-mail: amw79@medschl.cam.ac.uk. Hal Drakesmith,
Weatherall Institute of Molecular Medicine, University of Oxford,
Oxford, United Kingdom, E-mail: alexander.drakesmith@ndm.ox.ac.uk.
REFERENCES
1. Grantham-McGregor S, Ani C, 2001. A review of studies on the
effect of iron deficiency on cognitive development in children.
J Nutr 131: 649S–666S; discussion 666S–668S.
2. Burke RM, Leon JS, Suchdev PS, 2014. Identification, prevention
and treatment of iron deficiency during the first 1,000 days.
Nutrients 6: 4093–4114.
3. Roca-Feltrer A, Carneiro I, Smith L, Schellenberg JR, Greenwood
B, Schellenberg D, 2010. The age patterns of severe malaria
syndromes in sub-Saharan Africa across a range of transmission
intensities and seasonality settings. Malar J 9: 282.
4. Murphy SC, Breman JG, 2001. Gaps in the childhood malaria
burden in Africa: cerebral malaria, neurological sequelae,
anemia, respiratory distress, hypoglycemia, and complications
of pregnancy. Am J Trop Med Hyg 64: 57–67.
5. Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen
BK, Ganz T, 2004. IL-6 mediates hypoferremia of inflamma-
tion by inducing the synthesis of the iron regulatory hormone
hepcidin. J Clin Invest 113: 1271–1276.
6. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A,
Ward DM, Ganz T, Kaplan J, 2004. Hepcidin regulates cellular
iron efflux by binding to ferroportin and inducing its internali-
zation. Science 306: 2090–2093.
7. Rodriguez R, Jung CL, Gabayan V, Deng JC, Ganz T, Nemeth E,
Bulut Y, 2014. Hepcidin induction by pathogens and pathogen-
derived molecules is strongly dependent on interleukin-6. Infect
Immun 82: 745–752.
8. Kemna E, Pickkers P, Nemeth E, van der Hoeven H, Swinkels
D, 2005. Time-course analysis of hepcidin, serum iron, and
plasma cytokine levels in humans injected with LPS. Blood
106: 1864–1866.
9. Doherty CP, Cox SE, Fulford AJ, Austin S, Hilmers DC,
Abrams SA, Prentice AM, 2008. Iron incorporation and post-
malaria anaemia. PLoS One 3: e2133.
10. Cercamondi CI, Egli IM, Ahouandjinou E, Dossa R, Zeder C,
Salami L, Tjalsma H, Wiegerinck E, Tanno T, Hurrell RF,
Hounhouigan J, Zimmermann MB, 2010. Afebrile Plasmo-
dium falciparum parasitemia decreases absorption of fortifica-
tion iron but does not affect systemic iron utilization: a double
stable-isotope study in young Beninese women. Am J Clin
Nutr 92: 1385–1392.
11. Mabeza GF, Loyevsky M, Gordeuk VR, Weiss G, 1999. Iron
chelation therapy for malaria: a review. Pharmacol Ther 81:
53–75.
12. Clark MA, Goheen MM, Fulford A, Prentice AM, Elnagheeb
MA, Patel J, Fisher N, Taylor SM, Kasthuri RS, Cerami C,
2014. Host iron status and iron supplementation mediate sus-
ceptibility to erythrocytic stage Plasmodium falciparum. Nat
Commun 5: 4446.
13. Portugal S, Carret C, Recker M, Armitage AE, Goncalves LA,
Epiphanio S, Sullivan D, Roy C, Newbold CI, Drakesmith H,
Mota MM, 2011. Host-mediated regulation of superinfection
in malaria. Nat Med 17: 732–737.
14. Nyakeriga AM, Troye-Blomberg M, Dorfman JR, Alexander
ND, Back R, Kortok M, Chemtai AK, Marsh K, Williams TN,
2004. Iron deficiency and malaria among children living on
the coast of Kenya. J Infect Dis 190: 439–447.
15. Kabyemela ER, Fried M, Kurtis JD, Mutabingwa TK, Duffy PE,
2008. Decreased susceptibility to Plasmodium falciparum
infection in pregnant women with iron deficiency. J Infect Dis
198: 163–166.
16. Senga EL, Harper G, Koshy G, Kazembe PN, Brabin BJ, 2011.
Reduced risk for placental malaria in iron deficient women.
Malar J 10: 47.
17. Gwamaka M, Kurtis JD, Sorensen BE, Holte S, Morrison R,
Mutabingwa TK, Fried M, Duffy PE, 2012. Iron deficiency
protects against severe Plasmodium falciparum malaria and
death in young children. Clin Infect Dis 54: 1137–1144.
18. Sangare L, van Eijk AM, Ter Kuile FO, Walson J, Stergachis A,
2014. The association between malaria and iron status or sup-
plementation in pregnancy: a systematic review and meta-
analysis. PLoS One 9: e87743.
19. Sazawal S, Black RE, Ramsan M, Chwaya HM, Stoltzfus RJ,
Dutta A, Dhingra U, Kabole I, Deb S, Othman MK, Kabole
825CORD HEPCIDIN AND RISKS OF ANEMIA, MALARIA, AND MORTALITY
FM, 2006. Effects of routine prophylactic supplementation
with iron and folic acid on admission to hospital and mortality
in preschool children in a high malaria transmission setting:
community-based, randomised, placebo-controlled trial. Lancet
367: 133–143.
20. Veenemans J, Milligan P, Prentice AM, Schouten LR, Inja N,
van der Heijden AC, de Boer LC, Jansen EJ, Koopmans
AE, Enthoven WT, Kraaijenhagen RJ, Demir AY, Uges
DR, Mbugi EV, Savelkoul HF, Verhoef H, 2011. Effect of
supplementation with zinc and other micronutrients on
malaria in Tanzanian children: a randomised trial. PLoS
Med 8: e1001125.
21. Drakesmith H, Prentice AM, 2012. Hepcidin and the iron-infection
axis. Science 338: 768–772.
22. Kabyemela E, Goncalves BP, Prevots DR, Morrison R, Harrington
W, Gwamaka M, Kurtis JD, Fried M, Duffy PE, 2013. Cytokine
profiles at birth predict malaria severity during infancy. PLoS
One 8: e77214.
23. World Health Organization, Department of Nutrition for Health
and Development, 2001. Iron Deficiency Anaemia: Assessment,
Prevention and Control: A Guide for Programme Managers.
Geneva, Switzerland: World Health Organization.
24. Prentice AM, Doherty CP, Abrams SA, Cox SE, Atkinson SH,
Verhoef H, Armitage AE, Drakesmith H, 2012. Hepcidin
is the major predictor of erythrocyte iron incorporation in
anemic African children. Blood 119: 1922–1928.
25. Coutinho HM, McGarvey ST, Acosta LP, Manalo DL, Langdon
GC, Leenstra T, Kanzaria HK, Solomon J, Wu H, Olveda
RM, Kurtis JD, Friedman JF, 2005. Nutritional status and
serum cytokine profiles in children, adolescents, and young
adults with Schistosoma japonicum-associated hepatic fibrosis,
in Leyte, Philippines. J Infect Dis 192: 528–536.
26. Chong SS, Boehm CD, Higgs DR, Cutting GR, 2000. Single-
tube multiplex-PCR screen for common deletional determi-
nants of α-thalassemia. Blood 95: 360–362.
27. Fibrinogen Studies CKaptoge S, White IR, Thompson SG, Wood
AM, Lewington S, Lowe GD, Danesh J, 2007. Associations of
plasma fibrinogen levels with established cardiovascular dis-
ease risk factors, inflammatory markers, and other character-
istics: individual participant meta-analysis of 154,211 adults in
31 prospective studies: the Fibrinogen Studies Collaboration.
Am J Epidemiol 166: 867–879.
28. Easton DF, Peto J, Babiker AG, 1991. Floating absolute risk: an
alternative to relative risk in survival and case-control anal-
ysis avoiding an arbitrary reference group. Stat Med 10:
1025–1035.
29. Nweneka CV, Doherty CP, Cox S, Prentice A, 2010. Iron
delocalisation in the pathogenesis of malarial anaemia. Trans
R Soc Trop Med Hyg 104: 175–184.
30. de Mast Q, Nadjm B, Reyburn H, Kemna EH, Amos B,
Laarakkers CM, Silalye S, Verhoef H, Sauerwein RW,
Swinkels DW, van der Ven AJ, 2009. Assessment of urinary
concentrations of hepcidin provides novel insight into distur-
bances in iron homeostasis during malarial infection. J Infect
Dis 199: 253–262.
31. de Mast Q, Syafruddin D, Keijmel S, Riekerink TO, Deky O,
Asih PB, Swinkels DW, van der Ven AJ, 2010. Increased
serum hepcidin and alterations in blood iron parameters asso-
ciated with asymptomatic P. falciparum and P. vivax malaria.
Haematologica 95: 1068–1074.
32. Howard CT, McKakpo US, Quakyi IA, Bosompem KM, Addison
EA, Sun K, Sullivan D, Semba RD, 2007. Relationship of
hepcidin with parasitemia and anemia among patients with
uncomplicated Plasmodium falciparum malaria in Ghana. Am
J Trop Med Hyg 77: 623–626.
33. Casals-Pascual C, Huang H, Lakhal-Littleton S, Thezenas ML,
Kai O, Newton CR, Roberts DJ, 2012. Hepcidin demonstrates
a biphasic association with anemia in acute Plasmodium
falciparum malaria. Haematologica 97: 1695–1698.
34. Burte F, Brown BJ, Orimadegun AE, Ajetunmobi WA, Afolabi
NK, Akinkunmi F, Kowobari O, Omokhodion S, Osinusi K,
Akinbami FO, Shokunbi WA, Sodeinde O, Fernandez-Reyes
D, 2013. Circulatory hepcidin is associated with the anti-
inflammatory response but not with iron or anemic status in
childhood malaria. Blood 121: 3016–3022.
35. Atkinson SH, Uyoga SM, Armitage AE, Khandwala S,
Mugyenyi CK, Bejon P, Marsh K, Beeson JG, Prentice AM,
Drakesmith H, Williams TN, 2015. Malaria and age variably
but critically control hepcidin throughout childhood in Kenya.
EBioMedicine 2: 1478–1486.
36. Muehlenbachs A, Fried M, Lachowitzer J, Mutabingwa TK,
Duffy PE, 2007. Genome-wide expression analysis of placental
malaria reveals features of lymphoid neogenesis during chronic
infection. J Immunol 179: 557–565.
37. Van Santen S, de Mast Q, Luty AJ, Wiegerinck ET, Van der Ven
AJ, Swinkels DW, 2011. Iron homeostasis in mother and child
during placental malaria infection. Am J Trop Med Hyg 84:
148–151.
38. Marchini G, Berggren V, Djilali-Merzoug R, Hansson LO, 2000.
The birth process initiates an acute phase reaction in the
fetus-newborn infant. Acta Paediatr 89: 1082–1086.
39. Basu S, Kumar N, Srivastava R, Kumar A, 2016. Maternal and
cord blood hepcidin concentrations in severe iron deficiency
anemia. Pediatr Neonatol doi: 10.1016/j.pedneo.2015.09.012.
40. Rehu M, Punnonen K, Ostland V, Heinonen S, Westerman M,
Pulkki K, Sankilampi U, 2010. Maternal serum hepcidin is
low at term and independent of cord blood iron status. Eur J
Haematol 85: 345–352.
41. Lorenz L, Herbst J, Engel C, Peter A, Abele H, Poets CF,
Westerman M, Franz AR, 2014. Gestational age-specific ref-
erence ranges of hepcidin in cord blood. Neonatology 106:
133–139.
42. Martin ME, Nicolas G, Hetet G, Vaulont S, Grandchamp B,
Beaumont C, 2004. Transferrin receptor 1 mRNA is down-
regulated in placenta of hepcidin transgenic embryos. FEBS
Lett 574: 187–191.
43. Gambling L, Danzeisen R, Gair S, Lea RG, Charania Z,
Solanky N, Joory KD, Srai SK, McArdle HJ, 2001. Effect of
iron deficiency on placental transfer of iron and expression of
iron transport proteins in vivo and in vitro. Biochem J 356:
883–889.
44. Wang HZ, He YX, Yang CJ, Zhou W, Zou CG, 2011. Hepcidin
is regulated during blood-stage malaria and plays a protective
role in malaria infection. J Immunol 187: 6410–6416.
45. Goyal J, McCleskey B, Adamski J, 2013. Peering into the future:
hepcidin testing. Am J Hematol 88: 976–978.
46. Cangemi G, Pistorio A, Miano M, Gattorno M, Acquila M,
Bicocchi MP, Gastaldi R, Riccardi F, Gatti C, Fioredda F,
Calvillo M, Melioli G, Martini A, Dufour C, 2013. Diagnostic
potential of hepcidin testing in pediatrics. Eur J Haematol 90:
323–330.
47. Pasricha SR, Atkinson SH, Armitage AE, Khandwala S, Veenemans
J, Cox SE, Eddowes LA, Hayes T, Doherty CP, Demir AY,
Tijhaar E, Verhoef H, Prentice AM, Drakesmith H, 2014.
Expression of the iron hormone hepcidin distinguishes dif-
ferent types of anemia in African children. Sci Transl Med
6: 235re3.
48. Arezes J, Jung G, Gabayan V, Valore E, Ruchala P, Gulig PA,
Ganz T, Nemeth E, Bulut Y, 2015. Hepcidin-induced hypo-
ferremia is a critical host defense mechanism against the
siderophilic bacterium Vibrio vulnificus. Cell Host Microbe 17:
47–57.
49. Ganz T, 2003. Hepcidin, a key regulator of iron metabolism and
mediator of anemia of inflammation. Blood 102: 783–788.
826 BRICKLEY, SPOTTISWOODE AND OTHERS
